Brian Cheng
Stock Analyst at JP Morgan
(0.85)
# 3,715
Out of 4,761 analysts
60
Total ratings
28.57%
Success rate
-23.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Overweight | $51 → $53 | $38.75 | +36.77% | 4 | Feb 4, 2025 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $126 → $129 | $92.25 | +39.84% | 2 | Feb 4, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $3.77 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.92 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $14.39 | +25.09% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $15.74 | +77.89% | 4 | Nov 7, 2024 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $27 → $24 | $7.41 | +223.89% | 2 | Aug 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $61 → $55 | $12.17 | +351.93% | 3 | Aug 12, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $21.27 | +116.27% | 2 | Aug 8, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $39 → $33 | $2.78 | +1,087.05% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.36 | +154.24% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $9.52 | +152.10% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.91 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.53 | +837.73% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $2.17 | +268.66% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $10.68 | +40.45% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.41 | +3,330.53% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.63 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.97 | +516.40% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.96 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.40 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.31 | +1,426.72% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $17.77 | +378.33% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.21 | +128.01% | 1 | Aug 3, 2021 |
Protagonist Therapeutics
Feb 4, 2025
Maintains: Overweight
Price Target: $51 → $53
Current: $38.75
Upside: +36.77%
Blueprint Medicines
Feb 4, 2025
Maintains: Overweight
Price Target: $126 → $129
Current: $92.25
Upside: +39.84%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $3.77
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.92
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $14.39
Upside: +25.09%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $15.74
Upside: +77.89%
iTeos Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $27 → $24
Current: $7.41
Upside: +223.89%
Intellia Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $61 → $55
Current: $12.17
Upside: +351.93%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $21.27
Upside: +116.27%
Kyverna Therapeutics
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $2.78
Upside: +1,087.05%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.36
Upside: +154.24%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $9.52
Upside: +152.10%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.91
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.53
Upside: +837.73%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.17
Upside: +268.66%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $10.68
Upside: +40.45%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.41
Upside: +3,330.53%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.97
Upside: +516.40%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.96
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.40
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $1.31
Upside: +1,426.72%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $17.77
Upside: +378.33%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.21
Upside: +128.01%